Brandon J Webb1, Jeffrey Sorensen2, Ian Mecham3, Whitney Buckel4, Lilian Ooi5, Al Jephson2, Nathan C Dean6. 1. Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, UT; Division of Infectious Diseases and Geographic Medicine, Stanford Medicine, Palo Alto, CA. Electronic address: Brandon.Webb@imail.org. 2. Office of Research, Intermountain Healthcare, Salt Lake City, UT. 3. Division of Pulmonary and Critical Care, Utah Valley Regional Medical Center, Intermountain Healthcare, Provo, UT. 4. Department of Pharmacy, Intermountain Medical Center, Murray, UT. 5. Department of Pharmacy, Intermountain McKay Dee Hospital, Ogden, UT. 6. Division of Pulmonary and Critical Care Medicine, Intermountain Medical Center and the University of Utah, Salt Lake City, UT.
Abstract
BACKGROUND: To guide rational antibiotic selection in community-onset pneumonia, we previously derived and validated a novel prediction tool, the Drug-Resistance in Pneumonia (DRIP) score. In 2015, the DRIP score was integrated into an existing electronic pneumonia clinical decision support tool (ePNa). METHODS: We conducted a quasi-experimental, pre-post implementation study of ePNa with DRIP score (2015) vs ePNa with health-care-associated pneumonia (HCAP) logic (2012) in ED patients admitted with community-onset pneumonia to four US hospitals. Using generalized linear models, we used the difference-in-differences method to estimate the average treatment effect on the treated with respect to ePNa with DRIP score on broad-spectrum antibiotic use, mortality, hospital stay, and cost, adjusting for available patient-level confounders. RESULTS: We analyzed 2,169 adult admissions: 1,122 in 2012 and 1,047 in 2015. A drug-resistant pathogen was recovered in 3.2% of patients in 2012 and 2.8% in 2015; inadequate initial empirical antibiotics were prescribed in 1.1% and 0.5%, respectively (P = .12). A broad-spectrum antibiotic was administered in 40.1% of admissions in 2012 and 33.0% in 2015 (P < .001). Vancomycin days of therapy per 1,000 patient days in 2012 were 287.3 compared with 238.8 in 2015 (P < .001). In the primary analysis, the average treatment effect among patients using the DRIP score was a reduction in broad-spectrum antibiotic use (OR, 0.62; 95% CI, 0.39-0.98; P = .039). However, the average effects for ePNa with DRIP on mortality, length of stay, and cost were not statistically significant. CONCLUSIONS: Electronic calculation of the DRIP score was more effective than HCAP criteria for guiding appropriate broad-spectrum antibiotic use in community-onset pneumonia.
BACKGROUND: To guide rational antibiotic selection in community-onset pneumonia, we previously derived and validated a novel prediction tool, the Drug-Resistance in Pneumonia (DRIP) score. In 2015, the DRIP score was integrated into an existing electronic pneumonia clinical decision support tool (ePNa). METHODS: We conducted a quasi-experimental, pre-post implementation study of ePNa with DRIP score (2015) vs ePNa with health-care-associated pneumonia (HCAP) logic (2012) in ED patients admitted with community-onset pneumonia to four US hospitals. Using generalized linear models, we used the difference-in-differences method to estimate the average treatment effect on the treated with respect to ePNa with DRIP score on broad-spectrum antibiotic use, mortality, hospital stay, and cost, adjusting for available patient-level confounders. RESULTS: We analyzed 2,169 adult admissions: 1,122 in 2012 and 1,047 in 2015. A drug-resistant pathogen was recovered in 3.2% of patients in 2012 and 2.8% in 2015; inadequate initial empirical antibiotics were prescribed in 1.1% and 0.5%, respectively (P = .12). A broad-spectrum antibiotic was administered in 40.1% of admissions in 2012 and 33.0% in 2015 (P < .001). Vancomycin days of therapy per 1,000 patient days in 2012 were 287.3 compared with 238.8 in 2015 (P < .001). In the primary analysis, the average treatment effect among patients using the DRIP score was a reduction in broad-spectrum antibiotic use (OR, 0.62; 95% CI, 0.39-0.98; P = .039). However, the average effects for ePNa with DRIP on mortality, length of stay, and cost were not statistically significant. CONCLUSIONS: Electronic calculation of the DRIP score was more effective than HCAP criteria for guiding appropriate broad-spectrum antibiotic use in community-onset pneumonia.
Authors: Jeremy A Irvin; Anuj Pareek; Jin Long; Pranav Rajpurkar; David Ken-Ming Eng; Nishith Khandwala; Peter J Haug; Al Jephson; Karen E Conner; Benjamin H Gordon; Fernando Rodriguez; Andrew Y Ng; Matthew P Lungren; Nathan C Dean Journal: J Thorac Imaging Date: 2021-09-23 Impact factor: 5.528
Authors: Nick J Tinker; Rachel A Foster; Brandon J Webb; Souha Haydoura; Whitney R Buckel; Edward A Stenehjem Journal: Antimicrob Steward Healthc Epidemiol Date: 2021-11-10
Authors: Jason R Carr; Barbara E Jones; Dave S Collingridge; Brandon J Webb; Caroline Vines; Blake Zobell; Todd L Allen; Rajendu Srivastava; Jenna Rubin; Nathan C Dean Journal: J Rural Health Date: 2020-11-26 Impact factor: 4.333
Authors: Nelson J Alvis-Zakzuk; Ivan Arroyave; Carlos Castañeda-Orjuela; Fernando De La Hoz-Restrepo; Nelson Alvis-Guzman Journal: BMJ Open Respir Res Date: 2020-11